The potential increased sensitivity afforded by Nanotrap sample processing in saliva could enable safer, earlier and more accurate recognition and response during an outbreak. The effective detection of Ebola, using a noninvasive sample collection technique, such as saliva collection, coupled with a delicate diagnostic test highly, all enabled by our Nanotrap particle technology, presents a very compelling solution for quick identification of infected people at a youthful stage of illness, says Emanuel Petricoin, codirector of the Center for Applied Proteomics and Molecular Medicine at Mason and cofounder of Ceres..For label growth, OPAXIO under review for marketplace authorization application acceptance in Europe and, based on positive Stage III data for pixantrone, we be prepared to file a rolling NDA in ’09 2009. Additionally, we continue steadily to focus on enhancing our capital structure, streamlining our functions and significantly reducing our money burn rate. With potential authorization of pixantrone and OPAXIO in ’09 2009, and potential sales revenue growth because of possible Zevalin label expansion, we are on focus on to accomplish our goal of reaching cashflow break-even in the fourth quarter of 2009, Bianco added. Targeted 2009 Milestones: ZEVALIN – – First – collection consolidation indication authorization for Zevalin with a focus on decision date by the FDA of April 2, 2009, based on a supplemental biologics license program submitted on October 2, 2008 for the usage of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin’s lymphoma.